ArticleDiabetic medicine : a journal of the British Diabetic Association2025
SARS-CoV-2 infection and new-onset type 1 diabetes in the post-acute period among children and young people in England.
Article in Diabetic medicine : a journal of the British Diabetic Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- SARS-CoV-2 infection and COVID-19 vaccination and the risk for new-onset type 1 diabetes: a register-based population study in Sweden.Diabetologia · 2026Article
- The silent epidemic within the pandemic: pathophysiology and prediction of post-COVID-19 diabetes.Journal of translational medicine · 2026Review
- SARS-CoV-2 infection and new-onset type 1 diabetes in the post-acute period among children and young people in England.Diabetic medicine : a journal of the British Diabetic Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsTo examine if SARS-CoV-2 infection is associated with new-onset type 1 diabetes in the post-acute period in children and young people (CYP).
methodsIn this population cohort, we used data on all hospital activity in England to estimate type 1 diabetes incidence among CYP aged 0-17 exposed to SARS-CoV-2 between May 2020 and August 2022, from day 28 after a positive test for the following 6 months. We compared this with unexposed CYP who were hospitalized for elective procedures or following trauma during the pandemic, and in the 2 years prior to the pandemic (historic cohorts). We excluded CYP with prior chronic illnesses. We undertook Cox regression analyses adjusted for age, sex, ethnicity, deprivation and season of index date, and stratified by periods when different SARS-CoV-2 variants were dominant.
resultsThere were 1,087,604 CYP in the exposed cohort, 143,748 in the trauma cohort, 253,368 in the elective cohort, 160,925 in the historic trauma cohort and 388,673 in the historic elective cohort. Hazard of developing type 1 diabetes was significantly higher among those exposed than unexposed CYP: 2.4 [1.58-3.64] relative to the trauma cohort, 2.9 [2.00-4.13] relative to the elective cohort, 4.2 [2.56-7.04] relative to the historic trauma cohort and 2.4 [1.81-3.10] relative to the historic elective cohort. Associations may be strongest during the Delta period.
conclusionsSARS-CoV-2 infection is associated with subsequent incident type 1 diabetes in the 1-7 months after an acute infection in previously healthy CYP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.